Setanaxib not checked

Asahi Kasei Therapeutics, AB · GKT137831 · NOX1/4 inhibitor

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
5 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment”In the company’s words, NCT02010242 on ClinicalTrials.gov
Tested for
Phase 1 (2 trials), Type 2 Diabetes Mellitus With Diabetic Nephropathy, Primary Biliary Cirrhosis, Alport Syndrome
Main trialPhase 2
“NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor. The primary objective of this study is to evaluate the efficacy of oral GKT137831 in patients with residual albuminuria despite maximal inhibition of the renin angiotensin aldosterone system.”In the company’s words, NCT02010242 on ClinicalTrials.gov
Other names
GKT137831 · NOX1/4 inhibitor

Other drugs for Phase 1

All 560 drugs for Phase 1

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Completed Feb 2015 Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Phase 2Completed 11 Apr 2019 Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
Phase 1/2Completed 24 Jun 2025 A Study to Evaluate Setanaxib in Patients With Alport Syndrome
Phase 1Completed 6 Feb 2019 Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets
Phase 1Completed 23 Mar 2021 Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Setanaxib

Following is part of Solo: you see every change to Setanaxib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in